Observational analysis shows reduced soft tissue inflammation in peri-implant mucositis, indicating therapeutic options may enhance oral health.
Supplementing 0.12% CHX with bioflavonoids provides added clinical benefits when used as an adjunct to mechanical debridement (MD) in patients with peri-implant mucositis. This combined approach appears more effective than 0.12% CHX alone in reducing peri-implant soft-tissue inflammation and P. gingivalis carriage, indicating that bioflavonoid-enriched formulations may represent a valuable therapeutic option in routine clinical practice for improving peri-implant health.
No takes yet. Share an insight, caveat, or question.
ALHarthi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: